van Rooij: Molecular Cardiology

Back to research groups

The Van Rooij group aims to delineate signaling pathways relevant for heart repair and remodeling that can eventually lead to effective treatment options to minimize the loss of cardiomyocytes and/or reverse the adverse remodeling processes in the diseased heart.

A major challenge in the field of cardiac biology is to decipher the relevance of different signaling mechanisms that are relevant during disease. Using mouse genetics in combination with novel sequencing technologies our lab is able to identify key cell types or candidate factors important for specific remodeling and repair processes of the heart. These factors are studied in detail by molecular gain and loss-of-function studies, applying both genetics and oligonucleotide-based approaches.

Key publications

Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner

Monika M Gladka, Arwa Kohela, Bas Molenaar, Danielle Versteeg, Lieneke Kooijman, Jantine Monshouwer-Kloots, Veerle Kremer, Harmjan R Vos, Manon M H Huibers, Jody J Haigh, Danny Huylebroeck, Reinier A Boon, Mauro Giacca, Eva van Rooij

Nat. Commun. (2021) 12:84

Download|2021

Single-cell sequencing of the healthy and diseased heart reveals Ckap4 as a new modulator of fibroblasts activation.

Gladka MM, Molenaar B, de Ruiter H, Versteeg D, Lacraz GPA, van der Elst S, Huibers MMH, van Oudenaarden A, van Rooij E.

Circulation 138:166–180

Download|2018

Single-cell transcriptomics following ischemic injury identifies a role for B2M in cardiac repair

Molenaar B, Timmer LT, Droog M, Perini I, Versteeg D, Kooijman L, Monshouwer-Kloots J, de Ruiter H, Gladka MM, van Rooij E

Commsbio. (2021) 4:146

2901

Tomo-seq identifies SOX9 as a key regulator of cardiac fibrosis during ischemic injury.

Lacraz GPA, Junker JP, Gladka MM, Molenaar B, Scholman KT, Vigil-Garcia M, Versteeg D, de Ruiter H, Vermunt MW, Creyghton MP, Huibers MMH, de Jonge N, van Oudenaarden A, van Rooij E.

Circulation 136:1396-1409

Download|2017

Postnatal cardiac gene-editing using CRISPR/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption.

Johansen AK, Molenaar B, Versteeg D, Leitoguinho AR, Demkes CJ, Spanjaard B, de Ruiter H, Akbari Moqadam FA, Kooijman L, Zentilin L, Giacca M, van Rooij E.

Circ. Res. 121(10):1168-1181.

Download|2017

Control of stress-dependent cardiac growth and gene expression by a microRNA.

van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN.

Science 316(5824): 575-579.

Download|2007

The efficacy of cardiac anti-miR-208a therapy is stress dependent.

Eding JE, Demkes CJ, Lynch JM, Seto AG, Montgomery RL, Semus HM, Jackson AL, Isabelle M, Chimenti S, van Rooij E.

Mol Ther. 25(3):694-704.

Download|2017

Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodeling

Marta Vigil-Garcia, Charlotte J Demkes, Joep E C Eding, Danielle Versteeg, Hesther de Ruiter, Ilaria Perini, Lieneke Kooijman, Monika M Gladka, Folkert W Asselbergs, Aryan Vink, Magdalena Harakalova, Alexander Bossu, Toon A B van Veen, Cornelis J Boogerd, Eva van Rooij

Cardiovasc. Res. cvaa233

Download|2020

CRISPR Craze to Transform Cardiac Biology

Sebastiaan Johannes van Kampen, Eva van Rooij

Trends Mol Med . 2019 Sep;25(9):791-802

2019

N Engl J Med. 374(1):85-7.

Download|2016

MicroRNA mimicry blocks pulmonary fibrosis.

Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, Kaminski N, van Rooij E

EMBO Mol Med 6(10):1347-56.

Download|2014

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.

Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E.

Circulation 124(14): 1537-1547.

Download|2011

Inhibition of miR-15 protects against cardiac ischemic injury.

Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E.

Circ Res 6 110(1): 71-81.

Download|2012

Group leader

Eva van Rooij

Eva van Rooij is group leader at the Hubrecht Institute and professor of Molecular Cardiology at the University Medical Center Utrecht. Her group aims to unveil the molecular signaling pathways that are relevant for cardiac disease. The Van Rooij group combines mouse genetics and models of heart disease with novel sequencing technologies such as single-cell sequencing and Tomo-seq to identify key cell types or candidate factors important for specific remodeling and repair processes of the heart. The ultimate goal is to identify pathways that can eventually lead to effective treatment options to minimize the loss of cardiomyocytes and/or reverse the adverse remodeling processes in the diseased heart.

Scientific training and positions

Awards

Current other activities


Group members

Eva van Rooij

Group Leader

Hesther de Ruiter

Technician

Daniëlle Versteeg

Technician

Jantine Monshouwer-Kloots

Technician

Lieneke Kooijman

Technician

Ilaria Perini

Technician

Monika Gladka-de Vries

Postdoc

Kees Jan Boogerd

Postdoc

Jenny Tsui

Postdoc

Andrea Mattiotti

Postdoc

Martijn Wehrens

Postdoc

Arwa Kohela

PhD Student

Maya Wright Clark

PhD Student

Sebastiaan van Kampen

PhD Student

Anne de Leeuw

PhD Student

Louk Timmer

PhD Student

Su Ji Han

PhD Student

Eirini Kyriakopoulou

PhD Student

Show all group members

Lab alumni